Zepbound approved for OSA

Obstructive sleep apnea is a sleep disorder in which the upper airway collapses again and again at night, cutting off breathing in short bursts. On Dec. 20, 2024, the FDA approved Zepbound as the first drug treatment for moderate to severe cases in adults with obesity. (fda.gov) The approval covers adults with obesity who have moderate to severe obstructive sleep apnea, and the drug is meant to be used with a reduced-calorie diet and more physical activity. Zepbound is tirzepatide, a once-weekly injection already sold for chronic weight management. (fda.gov) (zepbound.lilly.com) Sleep apnea is usually measured by the apnea-hypopnea index, or AHI, which counts how many times a person stops breathing or breathes too shallowly per hour of sleep. In the two studies behind the approval, patients got 10-mg or 15-mg weekly doses for 52 weeks, and the main goal was to cut that hourly event count. (fda.gov) The FDA said the trials enrolled 469 adults without type 2 diabetes, split between one study of people using positive airway pressure, or PAP, and one study of people who could not or would not use PAP. After 52 weeks, Zepbound beat placebo on breathing interruptions and on the share of patients who reached remission or mild disease with symptoms resolved. (fda.gov) In the phase 3 SURMOUNT-OSA trials published in The New England Journal of Medicine, tirzepatide reduced the apnea-hypopnea index by 25.3 events per hour more than placebo in the trial without PAP and by 29.3 events per hour more than placebo in the trial with PAP. The paper also reported estimated treatment differences in body weight of -16.1% and -17.3%, respectively. (nejm.org) Lilly said 42.2% of participants not using PAP and 50.2% of participants using PAP had remission or mild obstructive sleep apnea with no symptoms after one year on tirzepatide. Those figures help explain why the FDA framed the decision as a treatment option for certain patients, not a replacement for every existing therapy. (investor.lilly.com) (fda.gov) The agency also drew a direct line between the sleep-apnea benefit and weight loss. Its approval notice said the improvement in breathing during sleep is likely related to the body-weight reduction produced by tirzepatide. (fda.gov) That matters because PAP machines remain the standard treatment for moderate to severe obstructive sleep apnea, but many patients do not use them consistently or cannot tolerate them. The Zepbound studies were designed around that reality by testing the drug both with PAP and without it. (fda.gov) The label still carries the same major safety warnings seen in obesity treatment, including a boxed warning about thyroid C-cell tumors seen in rats and common stomach-related side effects such as nausea, diarrhea, vomiting and constipation. The FDA also says Zepbound should not be used with other tirzepatide products or with other glucagon-like peptide-1 receptor agonists. (accessdata.fda.gov) Lilly has also added a multi-dose, single-patient-use KwikPen for Zepbound, with four fixed weekly doses in each pen. The company’s current dosing materials list single-dose pens, single-dose vials and the KwikPen as available presentations for adults with obesity, and the device instructions say each pen contains four doses. (zepbound.lilly.com) (pi.lilly.com) For patients, the change is simple to describe even if the biology is not: a disease long treated with masks and air pressure now also has an FDA-approved drug option tied to weight loss. For doctors, the next question is which patients with obesity and sleep apnea do best with a weekly shot, PAP, or both together. (fda.gov)